Inhibikase Therapeutics, Inc. (40)

Browse by Contract Category

Contracts

2020 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on December 4, 2020)
Amendment to Promissory Note by and between Inhibikase Therapeutics, Inc. and Flagship Consulting, Inc., dated October (Filed With SEC on November 3, 2020)
Lease Agreement, dated June 5, 2020, by and between Inhibikase Therapeutics, Inc. and Regus Management Group, LLC (Filed With SEC on July 23, 2020)
License Agreement, by and between Inhibikase Therapeutics, Inc. and Emory University, dated June 8, 2010 (Filed With SEC on July 23, 2020)
Collaborative Research and Development Agreement, by and between Inhibikase Therapeutics, Inc. and Sphaera Pharma Pte. Ltd., dated February 29, 2012 (Filed With SEC on July 23, 2020)
2020 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on November 3, 2020)
Warrant, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 25, 2020 (Filed With SEC on September 15, 2020)
Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated January 1, 2019 (Filed With SEC on September 15, 2020)
Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics Inc. and Milton H. Werner, Ph.D., dated June 13, 2020 (Filed With SEC on September 15, 2020)
Warrant, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 25, 2020 (Filed With SEC on September 15, 2020)
Amended and Restated Second Convertible Revolving Demand Promissory 2020 Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 31, 2020 (Filed With SEC on September 15, 2020)
Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated February 5, 2020 (Filed With SEC on September 15, 2020)
Letter Agreement to Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated September 11, 2020 (Filed With SEC on September 15, 2020)
Convertible Revolving Demand Promissory Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting Inc., dated April 3, 2018 (Filed With SEC on September 15, 2020)
2020 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on September 15, 2020)
Consulting Agreement, by and between Inhibikase Therapeutics Inc. and Flagship Consulting, Inc., dated April 1, 2018 (Filed With SEC on September 15, 2020)
Form of Inhibikase Therapeutics, Inc. Subscription Agreement (Filed With SEC on July 23, 2020)
Form of Consulting Agreement (Filed With SEC on July 23, 2020)
Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated June 15, 2018 (Filed With SEC on July 23, 2020)
Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated August 31, 2018 (Filed With SEC on July 23, 2020)
Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated July 19, 2018 (Filed With SEC on July 23, 2020)
Form of Underwriting Agreement, including the Form of Lock-Up Agreement (Filed With SEC on July 23, 2020)
Specimen common stock Certificate of the Registrant (Filed With SEC on July 23, 2020)
Second Convertible Revolving Demand Promissory 2019 Note, issued by Inhibikase Therapeutics, Inc. to Joseph Frattaroli, dated December 31, 2019 (Filed With SEC on July 23, 2020)
Form of Warrant to purchase common stock of the Registrant, issued to each of the investors named in Schedule A thereto (Filed With SEC on July 23, 2020)
Warrant dated October 5, 2018, issued by Inhibikase Therapeutics, Inc. to Kubera North America, Inc (Filed With SEC on July 23, 2020)
Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated January 1, 2020 (Filed With SEC on July 23, 2020)
Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated March 31, 2020 (Filed With SEC on July 23, 2020)
Form of Representatives Warrant (Filed With SEC on July 23, 2020)
Form of Late IPO Warrant (Filed With SEC on July 23, 2020)
Convertible Revolving Demand Promissory Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated April 3, 2018 (Filed With SEC on July 23, 2020)
Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics Inc. and Milton H. Werner, Ph.D., dated June 13, 2020 (Filed With SEC on July 23, 2020)
Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Joseph Frattaroli, dated October 24, 2018 (Filed With SEC on July 23, 2020)
Fifth Restatement and Amendment to Promissory Note, issued by Inhibikase Therapeutics, Inc. to McDaniel Law Firm, PC, dated June 30, 2020 (Filed With SEC on July 23, 2020)
First Amendment to Collaborative Research and Development Agreement, by and between Inhibikase Therapeutics Inc. and Sphaera Pharma Pte. Ltd., dated October 5, 2012 (Filed With SEC on July 23, 2020)
2011 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on July 23, 2020)
2020 Equity Incentive Plan (Filed With SEC on July 23, 2020)
Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, Ph.D, dated April 1, 2014 (Filed With SEC on July 23, 2020)
Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner Ph.D, to be in effect upon the completion of this offering (Filed With SEC on July 23, 2020)
Form of Inhibikase Therapeutics, Inc. Directors and Officers Indemnification Agreement (Filed With SEC on July 23, 2020)